Table 3 characteristics of the prescriptions

FQ prescribed

Ciprofloxacin: 253 (96.6%)

Moxifloxacin: 3 (1.1%)

Levofloxacin: 5 (1.9%)

Norfloxacin: 1 (0.4%)

Main indication

On-label

Respiratory infections in CF patients: 13 (5.0%)

Complicated UTI and pyelonephritis: 31 (11.8%)

Off-label

Prophylaxis of febrile neutropenia: 49 (18.7%)

Pneumonia: 34 (13.0%)

Multidrug-resistant tuberculosis: 1 (0.4%)

Sepsis: 6 (2.3%)

Ocular trauma: 1 (0.4%)

Intraabdominal abcess and peritonitis: 15 (5.7%)

Enteritis: 13 (5.0%)

Meningitis and/or encephalitis: 65 (24.8%)

Epididymitis: 2 (0.8%)

Skin and soft tissue infections: 27 (10.3%), including burns and surgical site infections

Osteomyelitis: 2 (0.8%)

Q-fever: 1 (0.4%)

Microbial cultures

None: 170 (64.9%)

Pseudomonas aeruginosa: 51 (19.5%)

Colonic bacteriae: 17 (6.5%)

(Escherichia coli, Enterobacter cloaca, Citrobacter freundi)

Stenotrophomonas maltophilia: 7 (2.7%)

Salmonalla species (blood culture): 3 (1.1%)

Klebsiella pneumoniae: 4 (1.5%)

Mycoplasma pneumoniae: 2 (0.8%)

Mycobacterium tuberculosis: 1 (0.4%)

Acinetobacter species: 1 (0.4%)

Proteus mirabilis: 1 (0.4%)

Neiseria meningitidis, serogroup B: 1 (0.4%)

Morganella morgani: 1 (0.4%)

Route of administration

Orally: 130 (49.6%)

IV: 132 (50.4%)

Doses per day

1: 5 (1.9%)

2: 240 (91.6%)

3: 17 (6.5%)

Dose adequate:

Adequate: 183 (69.8%)

Inadequate: 79 (30.2%)

Underdosing: 45 (56.9%)

Overdosing: 25 (31,6%)

Unnecessarily thrice daily dosing PO: 9 (11,4%)